UK-based clinical stage biopharmaceutical company Verona Pharma plc is on a mission to develop and commercialize therapies for respiratory diseases that have yet to see adequate medical attention. The company's primary product candidate, ensifentrine, is a dual inhibitor of phosphodiesterase (PDE) 3 and PDE4 enzymes that can simultaneously act as both a bronchodilator and an anti-inflammatory drug. With Phase 3 clinical trials underway, ensifentrine is being studied for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis in three formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc, established in 2005, is headquartered in London.
Verona Pharma plc's ticker is VRNA
The company's shares trade on the NASDAQ stock exchange
They are based in London, England
There are 11-50 employees working at Verona Pharma plc
It is https://www.veronapharma.com/
Verona Pharma plc is in the Healthcare sector
Verona Pharma plc is in the Biotechnology industry
The following five companies are Verona Pharma plc's industry peers: